Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

14th International Myeloma Workshop /
Multiple myeloma: transplant setting in the younger patient

3rd - 7th Apr 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.04.13
Views: 5490
Rating:

Prof Philippe Moreau, Prof Pieter Sonneveld and Prof Hartmut Goldschimdt

Prof Philippe Moreau, Prof Pieter Sonneveld and Prof Hartmut Goldschimdt come together for ecancertv at IMW 2013. High-dose therapy (HDT) with autologous stem cell transplant (ASCT) for multiple myeloma (MM) has been considered the standard of care for frontline treatment in younger patients with adequate organ function.

The introduction of novel agents, specifically thalidomide, bortezomib and lenalidomide, has changed the ASCT scenario in several ways.

Novel agents are now being incorporated as part of induction therapy and have been investigated for use on consolidation and maintenance post-ASCT.

The overall goal remains progression free survival and overall survival.

The efficacy of novel agents has led to the investigation of these agents upfront without ASCT, leading to much debate regarding the positioning of ASCT in the treatment of MM.

The role of allogeneic transplantation has been investigated in MM patients, and it may have a role in the treatment of high risk young patients or patients in first relapse.

 

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation